Neurocrine Biosciences | NBIX - صافي الدخل





صافي الدخل تغيير تاريخ
AbbVie USD 695M 1.12B 2026-03
Acadia Pharmaceuticals USD 3.64M 269.93M 2026-03
Agios Pharmaceuticals USD -99.11M 8.93M 2026-03
ALKERMES USD 49.34M 33.42M 2025-12
Alnylam Pharmaceuticals USD 205.99M 19.57M 2026-03
Amgen USD 1.82B 486M 2026-03
Biogen USD 319.5M 368.4M 2026-03
BioMarin Pharmaceutical USD 105.53M 152.1M 2026-03
Cytokinetics USD -206.03M 23M 2026-03
Enanta Pharmaceuticals USD -22.29M 93.76M 2024-12
Exelixis USD 244.53M 50.95M 2025-12
Gilead Sciences USD 2.18B 869M 2025-12
Halozyme Therapeutics USD -141.59M 316.82M 2025-12
Incyte USD 303.33M 4.05M 2026-03
Ionis Pharmaceuticals USD -93M 136M 2026-03
Nektar Therapeutics USD -36.08M 978K 2025-12
Neurocrine Biosciences USD 153.7M 55.8M 2025-12
Pfizer USD 2.69B 4.34B 2026-03
Prothena USD -21.59M 14.95M 2025-12
Regeneron Pharmaceuticals USD 727.2M 117.4M 2026-03
Repligen USD 8.33M 4.95M 2026-03
Rigel Pharmaceuticals USD 12.42M 13.45M 2024-09
Sarepta Therapeutics USD 330.96M 743.18M 2026-03
Teva Pharmaceutical Industries USD 369M 111M 2026-03
Ultragenyx Pharmaceutical USD -185M 56M 2026-03
Vertex Pharmaceuticals USD 1.03B 159.7M 2026-03
Xoma USD -17.24M 33.23M 2024-09